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| INTRODUC TI ON
The lipid kinases (PI3Kα, β, γ, and δ are involved in diverse cellular functions such as cell growth, proliferation, differentiation, motility, survival, and trafficking and have been targeted extensively for drug discovery to treat cancer, autoimmune, and inflammatory diseases. [1] [2] [3] [4] [5] [6] [7] [8] [9] These efforts have focused initially on pan-PI3K inhibitors, and subsequently on isoform-selective and dual isoform inhibitors. 8, [10] [11] [12] [13] Nearly 15 compounds of varying PI3K isoform selectivity have been explored in the clinic culminating in the launch of four drugs to treat different forms of cancers: idelalisib [Zylidig®, a PI3Kδ selective inhibitor], 5 ] duvelisib [Copiktra®, a dual PI3Kδγ inhibitor], 14 alpelsib [Piqray®, a PI3Kα inhibitor], 15 and copanlisib [Aliqopa®,BAY 80-6946, a dual PI3Kδα inhibitor]. 16 Dual inhibitors of PI3Kδ and PI3Kγ are considered high-value targets both for inflammation/ autoimmunity and oncology. 8, 9 Compelling preclinical biology of PI3Kδ/γ, initially garnered from gene knockout studies and later substantiated through the use of small-molecule inhibitors, 7, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] led to significant investments by the pharmaceutical industry in the last two decades reflected in approximately ~220 patent publications (~80% on PI3Kδ inhibitors, ~15% on PI3Kγ inhibitors, and ~5% for dual inhibitors). 9 Duvelisib (also known as IPI-145 13 ) is the only dual PI3Kδ/γ inhibitor approved to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL, 14 at a dose of 25 mg, twice-a-day, associated with dual δ/γ inhibition. Duvelisib demonstrated compelling activity in various preclinical models of autoimmunity, including arthritis, 13 however, efficacy could not be demonstrated in rheumatoid arthritis clinical trials 27 in the dose range associated with a predominant PI3Kδ inhibition (0.5-5 mg, twice a day, PO). It is speculated that a more balanced PI3Kδ/γ dual inhibitor, approaching an ideal ratio of 1:1 with an improved safety profile may be needed to treat chronic autoimmune conditions. Our efforts to identify such inhibitors resulted in the identification of HM5023507 ( Figure 1 ) whose preclinical pharmacology is summarized in this report. The structure-activity relationships and the medicinal chemistry efforts leading up to the identification of HM5023507 are summarized elsewhere. 28 
| MATERIAL S AND ME THODS

| Reagents
HM5023507 was synthesized by Hutchison MediPharma Limited.
Details on the source of other reagents can be found in the Supplementary Materials and Methods section. Duvelisib was used as a reference tool and was also synthesized by Hutchison MediPharma.
| Animals
Female Wistar rats (4-6 weeks old) were obtained from Shanghai SLAC Laboratory Animal Co. Ltd and kept under SPF conditions at the animal facility of HMP. Experiments using mice were conducted at Janssen. All animal procedures were approved by the respective institutional animal care and use committees (IACUCs).
| Off-target selectivity profile
The selectivity of HM5023507 was examined at a concentration of 10 µmol/L in a panel of ~50 GPCRs, ion channels and transporters (CEREP panel™).
| Binding activity to recombinant kinases
The kinase selectivity profile of HM5023507 was evaluated using the KINOMESCAN TM assay (DiscoveRx), an active site-directed competition binding assay for quantitative measurement of interactions of test compounds with more than 458 recombinant human kinases and disease-relevant mutant variants, at a concentration of 10 µmol/L. KINOME TM assays do not require ATP and thereby report true thermodynamic interaction affinities, as opposed to IC 50 values, which often depend on the ATP concentration used in such assays. In brief, DNA-tagged recombinant kinases are allowed to bind to ligands immobilized on beads in the presence of test compounds or vehicle (dimethyl sulfoxide). Test compounds that bind to kinase active site, sterically or allosterically interfere with the binding of the kinase with bead-immobilized ligand and are removed during a washing step. DNA-tagged kinases retained on the beads are quantitated by PCR amplification.
| Surface plasmon resonance (SPR) binding to PI3K Isoforms
Binding assays using label-free SPR-based technology (BIACORE™) were performed by Biosensor Tools. Histidine-tagged recombinant PI3K proteins were used in SPR assays: PI3Kα (heterodimer of full- 
| Binding activity to endogenous kinases in cell lysates
The binding of HM5023507 (1 µmol/L) to native kinases was examined via the KiNativ™ assay (ActivX Biosci), based on the use of biotinylated acyl phosphates of ATP (ATP probes) to irreversibly label protein kinases, lipid kinases and heat shock proteins on their conserved lysine residues in the ATP-binding pocket. 
| PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ enzymatic assays
The inhibitory effects of HM5023507 on kinase activity of PI3K
were determined in enzymatic assays in vitro or in a cellular context as per methods described elsewhere 28 and summarized in the Supplemental Materials and Methods Section.
| Anti-IgE-induced basophil activation assay in human whole blood
Basophil activation assay in human whole blood was performed using the FlowCast® basophil activation test according to the manufacturer's instructions (Bulmann Laboratories AG, Schönenbuch, Switzerland). 28 Briefly, healthy donor whole blood was pretreated with HM5023507 for 30 minutes and target immune cells were stimulated with anti-IgE (for PI3Kδ mediated mechanism), fMLP (for PI3Kγ mediated mechanism), or IL-3 (as a negative control). The ratio of CD63 + positive cells in HM5023507-treated blood as compared to the untreated control was used to determine the percentage inhibition. Data were plotted using Prism software and IC 50 values were determined.
| Human immune cell assays
The inhibitory potency of HM5023507 on PI3Kγ or PI3Kδ signaling was examined in either isolated immune cells, whole blood or under coculture experiments as per methods summarized in the Supplementary Materials and Methods section. Briefly, the effects of HM5023507 on PI3Kγ signaling were explored by studying IL-8
induced neutrophil shape change. 19, 29 The effects on PI3Kδ signaling were studied via anti-IgM-induced B cell function. 30 The effects of dual inhibition of PI3Kγ/δ in immune cells were studied via changes in T cell activation, differentiation, Treg function, and T/B coculture assays mimicking the germinal center reaction.
| T and B cell coculture
The assay system (DiscoverRx) consists of a coculture of T/B cells with peripheral blood mononuclear cells stimulated with anti-IgM and a mild T cell stimulation cocktail containing Staphylococcal Enterotoxin B 0.02 ng/mL) and Toxic Shock Syndrome Toxin-1 (TSST; 0.02 ng/mL) for 84 hours. 31 Inclusion of a test compound in this assay allows evaluation of its impact on B and T cell activation leading to proliferation, cytotoxicity and the secretion of cytokines including TNFα, IL-6, IL-2, IL-17A, and IL-17F, and natural antibody production (IgG).
| Measurement of immune cell populations in blood from compound dosed rats
Female Wistar rats were orally dosed with HM5023507 dissolved in 20% hydroxypropyl-beta-cyclodextrin (HPCD) or vehicle (HPCD) and blood samples were collected at different time points postdosing. Immune cell populations in the blood samples were measured by a differential blood cell counter (SYSMEX XT2000iv). The plasma concentrations of HM5023507 were determined by liquid chromatography coupled with triple quadrupole mass spectrometer (LC-MS/MS) method with the lower limit of quantification (LLOQ) of 1 ng/mL.
| Con-A-induced cytokine production in rats
Female Wistar rats were orally dosed with HM5023507 dissolved in HPCD or vehicle (HPCD), given a Con-A (30 mg/kg, iv, Sigma-Aldrich) challenge 0.5 hour or 6.5 hour after oral dosing and euthanized for blood collection 1.5 hour post-Con-A challenge. Serum and plasma samples were respectively processed for quantitation of IFNγ (R&D systems) or HM5023507. 
| Anti-IgD-induced B cell activation in rat whole blood
| Chemokine-driven neutrophil migration into rat subcutaneous air pouch
The assay methodology was adopted from Winkler et al. 13 The 
| Type II collagen-induced arthritis in rats
CIA was induced as per methods outlined in Jia et al. 28 Briefly, 
| RE SULTS
The results are organized into the following sections: (a) PI3K δγ dual 
| HM5023507 is a Potent and Selective PI3Kδγ Dual Inhibitor
In in vitro biochemical assays, HM5023507 potently inhibited the kinase activity of both PI3Kγ and PI3Kδ ( Table   S1 ). In addition, interaction with PI3KC2G, a Class II PI3K was also observed. In additional assays, preferential interaction of HM5023507 to class I PI3K vs class II PI3K was demonstrated (see below).
The Kinativ™ platform was used to assess binding interactions of HM5023507 (1 µmol/L) with native cellular kinases in lysates from Jurkat T cells, and rat dog and cynomolgus leukocytes. HM5023507
showed ≥85% binding to endogenous PI3Kγ and PI3Kδ in cell lysates from the different species evaluated (Supplementary Section, Table   S2 ). The binding affinity to PI3Kβ varied somewhat by species, with low interaction in rat WBC lysates (46%), moderate in dog and monkey WBC lysates (78% and 70%, respectively), and significant binding in Class II and III PI3Ks demonstrating its PI3K class selectivity.
The binding of HM5023507 to native kinases in intact human PBMC and rat leukocytes was also explored (Supplementary Section, Table S3 ). HM5023507 potently bound to both PI3Kγ and PI3Kδ in human PBMC (IC 50 values of ~100 and 40 nmol/L, respectively) with selectivity against PI3Kβ (IC 50 > 1 µmol/L). Table 3 ). The selectivity ratio among the 3 isoforms for HM5023507, with its PI3Kδ IC 50 value [mean], is equated to 1, was 1(δ):0.5(γ): 151 (β).
| Effects of HM5023507 on immune function
The effects of HM5023507 on immune function were examined using diverse primary human immune cells (T and B cells, and neutrophils and basophils). In addition, the effects of the compound were also examined in rat and human whole blood, a complex biological matrix.
| Activation and differentiation of human T cells, and human Treg Function
Both PI3Kγ and PI3Kδ have been suggested to play a role in T cell activation. 23, [32] [33] [34] [35] HM5023507 attenuated anti-CD3/anti-CD28induced human T cell activation, with a better potency in the blockade of IL-2 production than in proliferation response, as indicated by its IC 50 values of 9 and 120 nmol/L (mean value), respectively (Supplementary Section, Table S4 ). T cell differentiation into Figure S1 ). If HM5023507 were to alter Treg suppressive function, then the suppressive effects of Tregs on the proliferative response of T effector cells would be expected to significantly be reduced. The results suggest that HM5023507 does not markedly affect the Treg function, an interpretation that is consistent with a selective sparing of human Tregs relative to CD4/CD8 T cells by pharmacological inhibitors of PI3K pathways. 36 
| Activation isolated human B cells, and B cells in human and rat blood
PI3Kδ is known to play a critical role in B cell activation. 3, 23, 24, 30 Consistent with its binding and inhibitory activities on PI3Kδ, 
| Human neutrophil activation
Activation of neutrophil IL-8 receptor by IL-8 triggers a shape change, a surrogate marker for the ensuing chemotactic response. PI3Kγ has been implicated in regulating chemokine GPCR signaling and chemotaxis. 23, 25, 26, 37 In accordance with this mechanism, HM5023507 inhibited IL-8 induced shape changes of purified human neutrophils with an average IC 50 value of 63 nmol/L (Supplementary Section, Table S5 ), and in whole blood, the inhibition was demonstrable at a higher concentration (average IC 50 1080 nmol/L).
| Human blood basophil activation
Basophil activation plays a key role in allergic inflammation.
Activation of basophils via IgE binding to the IgE high-affinity receptor or fMLP binding to the formyl peptide receptor 1 (FPR1) respectively involves PI3Kδ or PI3Kγ signaling. 23, 26, 38 As such, the basophil activation assay in human blood provides an opportunity to define Table S5 ). 
| Human T: B CoCultures
| Off-target activity
Potential off-target interactions of HM5023507 were investigated in a broad panel of 50 GPCR and ion-channel targets at a test concentration of 10 µmol/L (Supplementary Section, 
| Pharmacokinetics of HM5023507 in wistar rats and plasma protein binding
| Inhibition of PI3Kδ or PI3Kγ signaling in vivo
The inhibitory effects of HM5023507 on PI3Kδ or PI3Kγ isoforms 
| Immune cell trafficking
Physiological immune surveillance is ensured by continuous trafficking of immune cells throughout the body and recruitment to specific tissue compartments, such as secondary lymphoid organs, for mounting an immune response upon encounter with and recognition of antigens. PI3Ks regulate several aspects of migration such as gradient sensing via the regulation of chemokine signaling and cell motility. 7, 8, 19, 23, 29, 37, 39 Oral administration of HM5023507 led to rapid, dose-and time-dependent increases in circulating leukocytes, with modest increases in circulating neutrophils (Supplementary Section, Figure S2 ). These changes reflect disruption of chemokine/chemotactic signaling in lymphoid organs by HM5023507 leading to the emigration of immune cells into the circulation.
| Anti-inflammatory activity of HM5023507 in vivo
The anti-inflammatory activity of HM5023507 was examined using concanavalin-A-induced cytokine response and a rat collagen-induced arthritis. Figure S3 ). In rats, 
| Concanavalin-A-induced cytokine response
Con-A injection increased
| Collagen-induced arthritis
| Paw inflammation
| Plasma exposure in CIA model
Orally dosed HM5023507 showed dose-related increases in plasma exposure in animals with arthritic inflammation (Figure 6A These results indicate that exposure was related to total dose administered daily, and independent of dosing regimen. For example, plasma exposure seen with 0.6 mg/kg or 6 mg/kg given once day was fairly similar to that seen with 0.3 mg/kg or 3 mg/kg, given twice-a-day. 
| Collagen-specific Antibody Response
The effect of HM5023507 on the collagen-specific humoral response (ie, anti-collagen antibody production) was examined in serum samples collected at the beginning and the end of the dosing regimen. Arthritic animals showed robust anti-collagen humoral response (Figure 6 The profile of HM5023507 in the rat CIA model demonstrates its robust anti-inflammatory activity presumably mediated via its impact on various immune cells and pathways. As BID or QD regimens, associated with similar AUCs, led to the similar magnitude of reductions in paw inflammation, the anti-inflammatory activity of HM5023507 in the CIA model appears to be driven, in part, by systemic exposure as measured by the AUC.
The estimates of the duration of target coverage based on plasma exposures in the CIA model are summarized in Table 6 . In the BID regimen, at the approximate ED 50 dose of 0.3 mg/kg, the plasma concentrations were above the PI3Kδ/ PI3Kγ IC 50 levels for ~24 hours and ~6 hours, respectively. In the QD regimen, at the approximate ED 50 dose of 0.6 mg/kg, the plasma concentrations were above the PI3Kδ/ PI3Kγ IC 50 levels for ~20 hours and ~8 hours, respectively. At doses of ≥1 mg/kg (BID or QD), the plasma concentrations are above the PI3Kδ/ PI3Kγ IC 50 values for nearly 24 hours Given the ~eightfold difference in PI3Kδ/ PI3Kγ potency, the magnitude (ie, fold above IC 50 and IC 90 values) and the duration of coverage of PI3Kδγ will be influenced both by the dose, and the dosing regimen.
| D ISCUSS I ON
The efficacy of PI3K inhibitors in human cancers 5,14-16 is consistent with the evidence linking gain of function mutations in PI3Ks (α,β and γ) as drivers of malignancy. 4, 25, 26 Unfortunately, the efficacy often requires complete/sustained inhibition of PI3K signaling resulting in dose-limiting toxicities (eg, colitis, hepatitis, pneumonitis, hypertension, hyperglycemia, skin rash, and opportunistic infections), likely driven by the disruption of homeostatic innate/adaptive immune PI3K signaling. 17, 40 The genetic deletion of either PI3K δ or PI3Kγ or both isoforms in mice F I G U R E 5 HM5023507 (p.o.) attenuates concanavalin-A (Con-A)-induced inflammatory cytokine response in female Wistar rats. Ras were given HM5023507 or vehicle (t = 0 h), injected intravenously with Con-A (30 mg/kg) at t = 0.5 h, and euthanized for blood collection at t = 2 h Levels of serum IFNγ were determined using commercial kits, and plasma levels of HM5023507 were measured by LC-MS methods. Data were expressed as mean ± SEM (n = 4). Data were analyzed via one-way ANOVA, followed by Dunnett's test (***P < .001 vs Veh; ##P < .01 and ###P < .001 vs Veh + Con-A). In a separate experiment, HM5023507 (10 mg/kg, po; t = 0) attenuated Con-A (30 mg/kg, iv, t = 6.5 h) induced IFNγ levels measured at 8 h (ng/mL; mean + SE, n = 4 rats; Naïve: 10 ± 0, Con-A: 394 ± 36, HM5023507 ± Con-A: 46 ± 4, % Inhibition: 91%; plasma levels of HM5023507 (ng/mL; mean ± SD, n = 4) were 2740 + 612 The robust anti-inflmamatory activity of HM5023507 in the CIA model is consistent with the role of PI3Kδγ isoforms in autoimmune pathways. 7, 13, [42] [43] [44] Interestingly, QD and BID dosing regimens that resulted in similar plasma exposures, but differing degrees of PI3Kδγ coverage (Table 6) In summary, HM5023507 represents a highly selective, dual PI3Kδ/γ inhibitor with drug-like properties and robust in vitro/ in vivo pharmacology, coupled with consistent, translatable biology.
This overall profile makes it a useful tool to study the biology of PI3K δ/γ signaling.
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